$ZLAB
Stock $zlab

$zlab Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000162828023005832 Filed on March 01, 2023

Income Statement

Concept	2022 Q4	2022	2021
Revenue	$62.60M	$215.0M	$144.3M
YoY Change	41.73%	49.02%	194.49%
Cost Of Revenue	$20.92M	$74.02M	$52.20M
YoY Change	-3.58%	41.8%	212.57%
Gross Profit	$41.68M	$141.0M	$92.10M
YoY Change	85.48%	53.12%	186.02%
Gross Profit Margin	66.58%	65.58%	63.83%
Selling, General & Admin	$72.02M	$259.0M	$218.8M
YoY Change	3.51%	18.36%	96.59%
% of Gross Profit	172.81%	183.64%	237.57%
Research & Development	$66.95M	$286.4M	$573.3M
YoY Change	-61.1%	-50.04%	157.43%
% of Gross Profit	160.63%	203.09%	622.48%
Depreciation & Amortization	$2.127M	$8.227M	$6.490M
YoY Change	13.14%	26.76%	39.87%
% of Gross Profit	5.1%	5.83%	7.05%
Operating Expenses	$139.0M	$545.4M	$792.2M
YoY Change	-42.5%	-31.16%	137.11%
Operating Profit	-$97.29M	-$404.4M	-$700.1M
YoY Change	-55.61%	-42.24%	131.9%
Interest Expense	-$47.06M	$0.00	$2.200M
YoY Change	-4713.33%	-100.0%	-55.1%
% of Operating Profit
Other Income/Expense, Net	$82.58M	$3.113M	-$5.500M
YoY Change	1103.79%	-156.6%	-118.9%
Pretax Income	-$61.77M	-$443.3M	-$703.4M
YoY Change	-70.77%	-36.98%	162.66%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$61.77M	-$443.3M	-$704.5M
YoY Change	-70.84%	-37.08%	161.99%
Net Earnings / Revenue	-98.67%	-206.14%	-488.22%
Basic Earnings Per Share		-$0.46	-$0.76
Diluted Earnings Per Share	-$0.06	-$0.46	-$757.6K
COMMON SHARES
Basic Shares Outstanding		958.1M shares	929.9M shares
Diluted Shares Outstanding		958.1M shares	929.9M shares

Balance Sheet

Concept	2022 Q4	2022	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.008B	$1.008B	$1.409B
YoY Change	-28.43%	-28.43%	18.73%
Cash & Equivalents	$1.008B	$1.047M	$300.6M
Short-Term Investments	$0.00	$0.00	$445.0M
Other Short-Term Assets	$35.67M	$35.67M	$18.00M
YoY Change	98.19%	98.19%	65.14%
Inventory	$31.62M	$31.62M	$19.00M
Prepaid Expenses
Receivables	$39.96M	$39.96M	$47.50M
Other Receivables	$8.608M	$8.608M	$7.300M
Total Short-Term Assets	$1.124B	$1.124B	$1.501B
YoY Change	-25.09%	-25.09%	23.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.86M	$77.38M	$57.30M
YoY Change	0.98%	35.03%	22.17%
Goodwill
YoY Change
Intangibles	$1.511M
YoY Change	-18.24%
Long-Term Investments	$6.431M	$6.431M	$15.60M
YoY Change	-58.78%	-58.78%	1100.0%
Other Assets	$3.595M	$3.595M	$2.700M
YoY Change	33.15%	33.15%	42.11%
Total Long-Term Assets	$95.80M	$95.80M	$109.1M
YoY Change	-12.19%	-12.19%	33.7%
TOTAL ASSETS
Total Short-Term Assets	$1.124B	$1.124B	$1.501B
Total Long-Term Assets	$95.80M	$95.80M	$109.1M
Total Assets	$1.220B	$1.220B	$1.610B
YoY Change	-24.21%	-24.21%	24.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$65.97M	$65.97M	$126.2M
YoY Change	-47.72%	-47.72%	101.6%
Accrued Expenses	$38.74M	$38.74M	$31.60M
YoY Change	22.59%	22.59%	67.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$139.8M	$139.8M	$192.9M
YoY Change	-27.51%	-27.51%	96.84%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$34.70M	$37.10M
YoY Change	-100.0%	-6.46%	22.44%
Total Long-Term Liabilities	$0.00	$34.70M	$37.10M
YoY Change	-100.0%	-6.46%	22.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$139.8M	$139.8M	$192.9M
Total Long-Term Liabilities	$0.00	$34.70M	$37.10M
Total Liabilities	$174.5M	$174.5M	$230.0M
YoY Change	-24.11%	-24.11%	79.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.861B
YoY Change	31.26%
Common Stock	$2.893B
YoY Change	2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.046B	$1.046B	$1.380B
YoY Change
Total Liabilities & Shareholders Equity	$1.220B	$1.220B	$1.610B
YoY Change	-24.21%	-24.21%	24.08%

Cashflow Statement

Concept	2022 Q4	2022	2021
OPERATING ACTIVITIES
Net Income	-$61.77M	-$443.3M	-$704.5M
YoY Change	-70.84%	-37.08%	161.99%
Depreciation, Depletion And Amortization	$2.127M	$8.227M	$6.490M
YoY Change	13.14%	26.76%	39.87%
Cash From Operating Activities	-$109.3M	-$367.6M	-$549.2M
YoY Change	-28.56%	-33.06%	154.2%
INVESTING ACTIVITIES
Capital Expenditures	$4.373M	$24.59M	-$18.95M
YoY Change	-167.38%	-229.74%	77.6%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$445.0M	$268.9M
YoY Change	-100.0%	65.48%	-149.42%
Cash From Investing Activities	-$4.373M	$420.0M	$250.0M
YoY Change	-98.45%	68.03%	-145.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$824.5M
YoY Change			-27.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-199.0K	-$1.730M	820.2M
YoY Change	-28.93%	-100.21%	-27.57%
NET CHANGE
Cash From Operating Activities	-109.3M	-$367.6M	-549.2M
Cash From Investing Activities	-4.373M	$420.0M	250.0M
Cash From Financing Activities	-199.0K	-$1.730M	820.2M
Net Change In Cash	-113.9M	$44.37M	520.9M
YoY Change	-73.81%	-91.48%	44.08%
FREE CASH FLOW
Cash From Operating Activities	-$109.3M	-$367.6M	-$549.2M
Capital Expenditures	$4.373M	$24.59M	-$18.95M
Free Cash Flow	-$113.7M	-$392.2M	-$530.3M
YoY Change	-22.41%	-26.03%	158.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001704292
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	0	usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38205
CY2022	dei	Entity Registrant Name EntityRegistrantName	ZAI LAB LIMITED
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1144595
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4560 Jinke Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Bldg. 1, Fourth Floor Pudong
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Shanghai
CY2022	dei	Entity Address Country EntityAddressCountry	CN
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	201210
CY2022	dei	City Area Code CityAreaCode	86 21
CY2022	dei	Local Phone Number LocalPhoneNumber	6163 2588
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	3200000000	usd
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Firm AuditorFirmId	1113
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2021	dei	Auditor Name AuditorName	Deloitte Touche Tohmatsu Certified Public Accountants LLP
CY2021	dei	Auditor Location AuditorLocation	Shanghai, the People’s Republic of China
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008470000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	964100000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	445000000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39963000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47474000	usd
CY2022Q4	us-gaap	Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	8608000	usd
CY2021Q4	us-gaap	Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	7335000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	31621000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	18951000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	35674000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18021000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1124336000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1500881000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	803000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	803000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	6431000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	15383000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	6431000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	15605000	usd
CY2022Q4	zlab	Prepayments For Equipment PrepaymentsForEquipment	1396000	usd
CY2021Q4	zlab	Prepayments For Equipment PrepaymentsForEquipment	989000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57863000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43102000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19512000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14189000	usd
CY2022Q4	zlab	Land Use Rights Net Noncurrent LandUseRightsNetNoncurrent	6892000	usd
CY2021Q4	zlab	Land Use Rights Net Noncurrent LandUseRightsNetNoncurrent	7811000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1511000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1848000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1396000	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	870000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	0	usd
CY2021Q4	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	23858000	usd
CY2022Q4	us-gaap	Assets Assets	1220140000	usd
CY2021Q4	us-gaap	Assets Assets	1609956000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	65974000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	126163000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7050000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5927000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66818000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	60811000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	139842000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	192901000	usd
CY2022Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	21360000	usd
CY2021Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	27486000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13343000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9613000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	174545000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	230000000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000006
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000006
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	962455850	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	955363980	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	960219570	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	954981050	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2893120000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2825948000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1861360000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1418074000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	25685000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23645000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2236280	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	382930	shares
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	11856000	usd
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	4279000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1045595000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1379956000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1220140000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1609956000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212672000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144105000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48958000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	2368000	usd
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	207000	usd
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2022	us-gaap	Revenues Revenues	215040000	usd
CY2021	us-gaap	Revenues Revenues	144312000	usd
CY2020	us-gaap	Revenues Revenues	48958000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	74018000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	52239000	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	16736000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286408000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	573306000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	222711000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	258971000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	218831000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	111312000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-404357000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-700064000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-301801000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	14582000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	2190000	usd
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	5120000	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	0	usd
CY2020	us-gaap	Interest Expense InterestExpense	181000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-56403000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4661000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	21659000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3113000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10201000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7417000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-443065000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-703414000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-267786000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-221000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1057000	usd
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1119000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-443286000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-704471000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-268905000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	958067140	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	958067140	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	929921120	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	929921120	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	776677430	shares
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	746000	usd
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	776677430	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-443286000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-704471000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-268905000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	usd
CY2020	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	49330000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9121000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-19144000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-393956000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-713592000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-288049000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	294660000	usd
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6664000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	280549000	usd
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	850691000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24830000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-268905000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-19144000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1169345000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7417000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	839000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	818036000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	62250000	usd
CY2021	zlab	Issuance Cost Adjustment IssuanceCostAdjustment	65000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4279000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40714000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-704471000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9121000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1379956000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5870000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7577000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	61302000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-443286000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	49330000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1045595000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-443286000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-704471000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-268905000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10000	usd
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	477000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	1368000	usd
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	29000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8227000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6487000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4640000	usd
CY2022	zlab	Amortization Of Deferred Income AmortizationOfDeferredIncome	-2602000	usd
CY2021	zlab	Amortization Of Deferred Income AmortizationOfDeferredIncome	-521000	usd
CY2020	zlab	Amortization Of Deferred Income AmortizationOfDeferredIncome	-312000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	61302000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	40714000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	24830000	usd
CY2022	zlab	Noncash Research And Development Expenses NoncashResearchAndDevelopmentExpenses	0	usd
CY2021	zlab	Noncash Research And Development Expenses NoncashResearchAndDevelopmentExpenses	62250000	usd
CY2020	zlab	Noncash Research And Development Expenses NoncashResearchAndDevelopmentExpenses	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-221000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1057000	usd
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1119000	usd
CY2022	zlab	Loss On Fair Value Changes Of Equity Investment With Readily Determinable Fair Value LossOnFairValueChangesOfEquityInvestmentWithReadilyDeterminableFairValue	8952000	usd
CY2021	zlab	Loss On Fair Value Changes Of Equity Investment With Readily Determinable Fair Value LossOnFairValueChangesOfEquityInvestmentWithReadilyDeterminableFairValue	14617000	usd
CY2020	zlab	Loss On Fair Value Changes Of Equity Investment With Readily Determinable Fair Value LossOnFairValueChangesOfEquityInvestmentWithReadilyDeterminableFairValue	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-560000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	usd
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	21000	usd
CY2022	zlab	Non Cash Lease Expenses NonCashLeaseExpenses	8350000	usd
CY2021	zlab	Non Cash Lease Expenses NonCashLeaseExpenses	6119000	usd
CY2020	zlab	Non Cash Lease Expenses NonCashLeaseExpenses	4318000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-56403000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	10679000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	21659000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4330000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42319000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1375000	usd
CY2022	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	1976000	usd
CY2021	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	7335000	usd
CY2020	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	0	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15382000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7174000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7168000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19258000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7086000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4199000	usd
CY2022	zlab	Increase Decrease In Long Term Deposits IncreaseDecreaseInLongTermDeposits	527000	usd
CY2021	zlab	Increase Decrease In Long Term Deposits IncreaseDecreaseInLongTermDeposits	8000	usd
CY2020	zlab	Increase Decrease In Long Term Deposits IncreaseDecreaseInLongTermDeposits	485000	usd
CY2022	zlab	Increase Decrease In Value Added Taxes Receivable IncreaseDecreaseInValueAddedTaxesReceivable	-22781000	usd
CY2021	zlab	Increase Decrease In Value Added Taxes Receivable IncreaseDecreaseInValueAddedTaxesReceivable	1717000	usd
CY2020	zlab	Increase Decrease In Value Added Taxes Receivable IncreaseDecreaseInValueAddedTaxesReceivable	8404000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-53773000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	63522000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	39981000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	7392000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	30142000	usd
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	10682000	usd
CY2022	zlab	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-8455000	usd
CY2021	zlab	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5385000	usd
CY2020	zlab	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3416000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1379000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	11149000	usd
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	14289000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-367642000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-549231000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-216055000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	260274000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	445000000	usd
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	949161000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	705274000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	743902000	usd
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	405000000	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	30000000	usd
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24585000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18295000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10130000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	usd
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	399000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	653000	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	539000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	420016000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	249957000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-554830000	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2020	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	6527000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5870000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7417000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6664000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	818875000	usd
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1137683000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1837000	usd
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5380000	usd
CY2022	zlab	Employee Taxes Paid Related To Settlement Of Equity Awards EmployeeTaxesPaidRelatedToSettlementOfEquityAwards	-7600000	usd
CY2021	zlab	Employee Taxes Paid Related To Settlement Of Equity Awards EmployeeTaxesPaidRelatedToSettlementOfEquityAwards	-4253000	usd
CY2020	zlab	Employee Taxes Paid Related To Settlement Of Equity Awards EmployeeTaxesPaidRelatedToSettlementOfEquityAwards	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1730000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	820202000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1132440000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-6274000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1116000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4862000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	44370000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	522044000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	366417000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	964903000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	442859000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	76442000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1009273000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	964903000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	442859000	usd
CY2021	zlab	Receivable Recognized For Disposal Of Property And Equipment ReceivableRecognizedForDisposalOfPropertyAndEquipment	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	5269000	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	2568000	usd
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	788000	usd
CY2022	zlab	Non Cash Payables For Intangible Assets NonCashPayablesForIntangibleAssets	163000	usd
CY2021	zlab	Non Cash Payables For Intangible Assets NonCashPayablesForIntangibleAssets	191000	usd
CY2020	zlab	Non Cash Payables For Intangible Assets NonCashPayablesForIntangibleAssets	70000	usd
CY2022	zlab	Non Cash Payable For Public Offering Costs NonCashPayableForPublicOfferingCosts	0	usd
CY2021	zlab	Non Cash Payable For Public Offering Costs NonCashPayableForPublicOfferingCosts	0	usd
CY2020	zlab	Non Cash Payable For Public Offering Costs NonCashPayableForPublicOfferingCosts	1063000	usd
CY2022	zlab	Non Cash Payables For Treasury Stock NonCashPayablesForTreasuryStock	2000	usd
CY2021	zlab	Non Cash Payables For Treasury Stock NonCashPayablesForTreasuryStock	26000	usd
CY2020	zlab	Non Cash Payables For Treasury Stock NonCashPayablesForTreasuryStock	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14801000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2183000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6393000	usd
CY2022	zlab	Receivable Recognized For Disposal Of Property And Equipment ReceivableRecognizedForDisposalOfPropertyAndEquipment	64000	usd
CY2020	zlab	Receivable Recognized For Disposal Of Property And Equipment ReceivableRecognizedForDisposalOfPropertyAndEquipment	0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008470000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	964100000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	442116000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	803000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	803000	usd
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	743000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1009273000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	964903000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	442859000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	189000	usd
CY2022Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	10
CY2022Q1	zlab	Common Stock Authorized Share Capital CommonStockAuthorizedShareCapital	30000	usd
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000006
CY2022Q1	zlab	American Depositary Share To Common Stock Conversion Ratio AmericanDepositaryShareToCommonStockConversionRatio	1
CY2022Q1	zlab	American Depositary Share To Common Stock Conversion Ratio AmericanDepositaryShareToCommonStockConversionRatio	10
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest Current FinancingReceivableAllowanceForCreditLossExcludingAccruedInterestCurrent	0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgements, and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, accrual of rebates, recognition of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, fair value of share-based compensation expenses, recoverability of deferred tax assets, and a lack of marketability discount of the ordinary shares issued in connection with license and collaboration arrangements (Note 16). These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates.
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest Current FinancingReceivableAllowanceForCreditLossExcludingAccruedInterestCurrent	0	usd
CY2019	zlab	Land Use Rights Lease Term LandUseRightsLeaseTerm	P30Y
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	600000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	300000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	100000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	0	usd
CY2022	zlab	Cash Grants Recorded In Other Income CashGrantsRecordedInOtherIncome	11500000	usd
CY2021	zlab	Cash Grants Recorded In Other Income CashGrantsRecordedInOtherIncome	4100000	usd
CY2020	zlab	Cash Grants Recorded In Other Income CashGrantsRecordedInOtherIncome	7300000	usd
CY2022	zlab	Reimbursement Period ReimbursementPeriod	P5Y
CY2022	zlab	Reimbursement Revenue Recognized ReimbursementRevenueRecognized	200000	usd
CY2021	zlab	Reimbursement Revenue Recognized ReimbursementRevenueRecognized	300000	usd
CY2020	zlab	Reimbursement Revenue Recognized ReimbursementRevenueRecognized	300000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	2400000	usd
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	200000	usd
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents, short-term investments, accounts receivable, and notes receivable. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents and short-term investments represent the maximum amount of loss due to credit risk. As of December 31, 2022 and 2021, all of the Company’s cash and cash equivalents and short-term investments were held by major financial institutions located in mainland China and international financial institutions outside of mainland China which management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are typically unsecured and are derived from product sales and collaborative arrangements. The Company manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances and limits the amount of credit extended based upon payment history and credit worthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain accounts receivable balances may be settled in the form of notes receivable. As of December 31, 2022, notes receivable represented bank acceptance promissory notes that are non-interest bearing and due within six months. Notes receivable were used to collect the receivables based on an administrative convenience, given these notes are readily convertible to be known amounts of cash. In accordance with the sales agreements, whether to use cash or bank acceptance promissory notes to settle the receivables is at the Company’s discretion, and this selection does not impact the agreed contractual purchase prices. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk </span></div>RMB is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market.
CY2022Q4	us-gaap	Cash And Due From Banks CashAndDueFromBanks	1007423000	usd
CY2021Q4	us-gaap	Cash And Due From Banks CashAndDueFromBanks	663472000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1047000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	300628000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008470000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	964100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008470000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	964100000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	445000000.0	usd
CY2021Q4	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	31600000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	19000000.0	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12156000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5632000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	19029000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13231000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	436000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	88000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	31621000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	18951000	usd
CY2022	zlab	Inventory Write Down Value InventoryWriteDownValue	500000	usd
CY2021	zlab	Inventory Write Down Value InventoryWriteDownValue	1400000	usd
CY2020	zlab	Inventory Write Down Value InventoryWriteDownValue	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	79927000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	59527000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22064000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16425000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57863000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43102000	usd
CY2022	us-gaap	Depreciation Depreciation	7700000	usd
CY2021	us-gaap	Depreciation Depreciation	6000000.0	usd
CY2020	us-gaap	Depreciation Depreciation	4300000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8774000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	6263000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	4539000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	8084000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	5840000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	4056000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14801000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2183000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6393000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7561000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6184000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4586000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1734000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	822000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	391000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21278000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	885000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20393000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.034
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.023
CY2022	zlab	Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Return RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturn	234009000	usd
CY2021	zlab	Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Return RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturn	190180000	usd
CY2020	zlab	Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Return RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturn	57355000	usd
CY2022	zlab	Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates And Sales Return RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebatesAndSalesReturn	21337000	usd
CY2021	zlab	Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates And Sales Return RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebatesAndSalesReturn	46075000	usd
CY2020	zlab	Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates And Sales Return RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebatesAndSalesReturn	8397000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212672000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144105000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48958000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212672000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144105000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48958000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	2400000	usd
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	200000	usd
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-443286000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-704471000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-268905000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	98000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	108000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	84000	usd
CY2022Q4	zlab	Deferred Tax Assets Research And Experimental Capitalization DeferredTaxAssetsResearchAndExperimentalCapitalization	22476000	usd
CY2021Q4	zlab	Deferred Tax Assets Research And Experimental Capitalization DeferredTaxAssetsResearchAndExperimentalCapitalization	0	usd
CY2020Q4	zlab	Deferred Tax Assets Research And Experimental Capitalization DeferredTaxAssetsResearchAndExperimentalCapitalization	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1787000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	usd
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1800000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2022Q4	zlab	Deferred Tax Assets Government Grants DeferredTaxAssetsGovernmentGrants	189000	usd
CY2021Q4	zlab	Deferred Tax Assets Government Grants DeferredTaxAssetsGovernmentGrants	496000	usd
CY2020Q4	zlab	Deferred Tax Assets Government Grants DeferredTaxAssetsGovernmentGrants	400000	usd
CY2022Q4	zlab	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	3378000	usd
CY2021Q4	zlab	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	3733000	usd
CY2020Q4	zlab	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	2069000	usd
CY2022Q4	zlab	Deferred Tax Assets Public Welfare Donations DeferredTaxAssetsPublicWelfareDonations	12947000	usd
CY2021Q4	zlab	Deferred Tax Assets Public Welfare Donations DeferredTaxAssetsPublicWelfareDonations	10246000	usd
CY2020Q4	zlab	Deferred Tax Assets Public Welfare Donations DeferredTaxAssetsPublicWelfareDonations	7627000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	241397000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	175101000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284072000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	94954000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284072000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	189684000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105134000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1483200000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1089700000	usd
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	605200000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	189684000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105134000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	94388000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	84550000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	189684000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31689000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	25685000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4080000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4319000	usd
CY2022Q4	zlab	Payables For Purchase Of Property And Equipment Current PayablesForPurchaseOfPropertyAndEquipmentCurrent	5269000	usd
CY2021Q4	zlab	Payables For Purchase Of Property And Equipment Current PayablesForPurchaseOfPropertyAndEquipmentCurrent	2568000	usd
CY2022Q4	zlab	Accrued Rebate To Distributors Current AccruedRebateToDistributorsCurrent	8443000	usd
CY2021Q4	zlab	Accrued Rebate To Distributors Current AccruedRebateToDistributorsCurrent	15001000	usd
CY2022Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	13283000	usd
CY2021Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	8817000	usd
CY2022Q4	zlab	Other Payables Current Liabilities OtherPayablesCurrentLiabilities	4054000	usd
CY2021Q4	zlab	Other Payables Current Liabilities OtherPayablesCurrentLiabilities	4421000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66818000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	60811000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-443286000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-443286000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-704471000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-704471000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-268905000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-268905000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	958067140	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	958067140	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	929921120	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	929921120	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	776677430	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	776677430	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	81015590	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.79
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y11M23D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	339570000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	22571050	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.37
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5151190	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7254030	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.66
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	91181420	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.05
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M20D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	115969000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	54682520	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.48
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y2M19D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	112582000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14300000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	170400000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	64800000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61302000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40714000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24830000	usd
CY2022Q4	zlab	Collaborative Arrangement Rights And Obligations Maximum Additional Milestone Payments CollaborativeArrangementRightsAndObligationsMaximumAdditionalMilestonePayments	5300400000	usd
CY2022	zlab	Cash Grants Recorded In Other Income CashGrantsRecordedInOtherIncome	11471000	usd
CY2021	zlab	Cash Grants Recorded In Other Income CashGrantsRecordedInOtherIncome	4113000	usd
CY2020	zlab	Cash Grants Recorded In Other Income CashGrantsRecordedInOtherIncome	7289000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-8952000	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-14617000	usd
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
CY2022	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	594000	usd
CY2021	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	303000	usd
CY2020	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	128000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3113000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10201000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7417000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001628280-23-005832-index-headers.html	Edgar Link	pending
0001628280-23-005832-index.html	Edgar Link	pending
0001628280-23-005832.txt	Edgar Link	pending
0001628280-23-005832-xbrl.zip	Edgar Link	pending
ex1039-sandlerseveranceagr.htm	Edgar Link	pending
ex1042-michelvounatsosxapp.htm	Edgar Link	pending
ex211-subsidiarieslist2022.htm	Edgar Link	pending
ex231-kpmgconsentfor2022fo.htm	Edgar Link	pending
ex232deloitteconsentletter.htm	Edgar Link	pending
exhibit1040-zailabxjsmiley.htm	Edgar Link	pending
exhibit1041-zailabxramad.htm	Edgar Link	pending
exhibit1041-zailabxramad001.jpg	Edgar Link	pending
exhibit1041-zailabxramad002.jpg	Edgar Link	pending
exhibit1041-zailabxramad003.jpg	Edgar Link	pending
exhibit1041-zailabxramad004.jpg	Edgar Link	pending
exhibit1041-zailabxramad005.jpg	Edgar Link	pending
exhibit1041-zailabxramad006.jpg	Edgar Link	pending
exhibit1041-zailabxramad007.jpg	Edgar Link	pending
exhibit1041-zailabxramad008.jpg	Edgar Link	pending
exhibit1041-zailabxramad009.jpg	Edgar Link	pending
exhibit1041-zailabxramad010.jpg	Edgar Link	pending
exhibit1041-zailabxramad011.jpg	Edgar Link	pending
exhibit1041-zailabxramad012.jpg	Edgar Link	pending
exhibit1041-zailabxramad013.jpg	Edgar Link	pending
exhibit1041-zailabxramad014.jpg	Edgar Link	pending
exhibit1041-zailabxramad015.jpg	Edgar Link	pending
exhibit1041-zailabxramad016.jpg	Edgar Link	pending
exhibit107-nonxemployeedir.htm	Edgar Link	pending
exhibit45-descriptionofsec.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zlab-20221231.htm	Edgar Link	pending
zlab-20221231.xsd	Edgar Link	pending
zlab-20221231x10kxexx311.htm	Edgar Link	pending
zlab-20221231x10kxexx312.htm	Edgar Link	pending
zlab-20221231x10kxexx321.htm	Edgar Link	pending
zlab-20221231x10kxexx322.htm	Edgar Link	pending
zlab-20221231_g1.jpg	Edgar Link	pending
zlab-20221231_g2.jpg	Edgar Link	pending
zlab-20221231_g3.jpg	Edgar Link	pending
zlab-20221231_g4.jpg	Edgar Link	pending
zlab-20221231_g5.jpg	Edgar Link	pending
zlab-20221231_g6.jpg	Edgar Link	pending
zlab-20221231_g7.jpg	Edgar Link	pending
zlab-20221231_g8.jpg	Edgar Link	pending
zlab-20221231_cal.xml	Edgar Link	unprocessable
zlab-20221231_def.xml	Edgar Link	unprocessable
zlab-20221231_lab.xml	Edgar Link	unprocessable
zlab-20221231_pre.xml	Edgar Link	unprocessable
zlab-20221231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZLAB
Stock $zlab

2022 Q4 Form 10-K Financial Statement

#000162828023005832 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZLAB Stock $zlab

2022 Q4 Form 10-K Financial Statement

#000162828023005832 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZLAB
Stock $zlab